Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis

BMC Cancer, Год журнала: 2025, Номер 25(1)

Опубликована: Март 27, 2025

Recent studies have identified a complex relationship between methylation patterns and the development of various cancers. Breast cancer (BC) is second leading cause mortality among women. Approximately 5–20% BC patients are at risk brain metastases (BCBM). Although 5-methylcytosine (m5C) has been as an important regulatory modifier, its distribution in BCBM not well understood. This study aimed to investigate m5C BCBM. Samples from (231-BR cells) (MDA-MB-231 groups were subjected comprehensive analysis long non-coding RNA (lncRNA) using methylated immunoprecipitation next-generation sequencing (MeRIP-seq). The expression levels genes adjacent tissues verified through quantitative real-time polymerase chain reaction (RT-qPCR). Enrichment pathway analyses Gene Ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) predict potential functions MeRIP-seq 23,934 peaks 21,236 BC. A total 9,480 annotated (BCBM) 8,481 mapped. Notably, 1,819 sites lncRNA upregulated BCBM, whereas 2,415 Significant hypermethylated lncRNAs included ENST00000477316, ENST00000478098 uc002gtt.1, hypomethylated ENST00000600912, ENST00000493668, ENST00000544651 ENST00000464989. These results by qPCR MeRIP-qPCR Considering strong association regulators lncRNA, we examined 13 observed significant differences normal tissues. In addition, interaction altered differentially expressed vitro was analyzed. GO KEGG pathways revealed that significantly associated with linked signaling pathways. uncovered variations compared findings provide new theoretical understanding mechanisms

Язык: Английский

---

Insights into the genetic and epigenetic mechanisms governing X-chromosome-linked-miRNAs expression in cancer; a step-toward ncRNA precision

International Journal of Biological Macromolecules, Год журнала: 2024, Номер unknown, С. 138773 - 138773

Опубликована: Дек. 1, 2024

Язык: Английский

---

piRNAs and circRNAs acting as diagnostic biomarkers in clear cell renal cell carcinoma

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Март 5, 2025

The discovery of diverse functions and mechanisms in cancer has underscored the significance emerging non-coding RNAs (ncRNAs), such as PIWI-interacting (piRNAs) circular (circRNAs), within clinical context cancer. Understanding their role clear cell renal carcinoma (ccRCC) is imperative necessitates comprehensive investigation. This study aims to further explore diagnostic potential piRNAs circRNAs for ccRCC. dysregulated ccRCC were identified using small RNA (sRNA) high-throughput sequencing technology, while expression samples was assessed by RT-qPCR. A paired t-test performed compare levels between adjacent tissues. Additionally, ROC curve analysis conducted evaluate specificity, sensitivity, area under (AUC) circRNAs. High-throughput revealed a significant downregulation 17 694 tissues, accompanied upregulation 5 490 RT-qPCR demonstrated markedly lower piR-has-150997, 133872, 132556, 154502, uniq-84737 group compared tissue (p < 0.05). When considering combined detection piR-hsa-150997, piR-hsa-133872, piR-hsa-132556, piR-hsa-154502, uniq_84737, circABCC1, circNETO2_006, circARID1B_037, AUC found be high at an approximate value = 0.878. performance uniq-84737, circARID1B_037 demonstrates promise model incorporating could serve ideal marker system with utility.

Язык: Английский

---

Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer

Experimental Hematology and Oncology, Год журнала: 2025, Номер 14(1)

Опубликована: Март 12, 2025

Abstract Purpose Circular RNA (circRNA) has emerged as a promising therapeutic molecule due to its enhanced stability and prolonged protein expression compared messenger (mRNA). Using circRNA construct transient Chimeric Antigen Receptor (CAR)-T cells can mitigate the limitations of conventional viral vector-based CAR-T approaches, such complex process long-term side effects. Methods The study first reconfirmed advantageous properties circRNA, focusing on efficiency. Electroporation conditions were then optimized for efficient delivery into human primary T cells. Subsequently, encoding anti-Delta-like Ligand 3 (DLL3) CAR was constructed, generated via electroporation. efficacy circRNA-based mRNA-based in both vitro vivo models, including subcutaneous orthotopic small cell lung cancer (SCLC) mouse models. Results CircRNA-based demonstrated superior against SCLC In experiments showed tumor-killing effects, while studies revealed complete elimination tumors These results underscored advantages therapy. Conclusions This validated feasibility circRNA-electroporation strategy therapy offered potentially effective approach treating SCLC, highlighting potential technologies advancing therapies. Graphic

Язык: Английский

---

SNHG family lncRNAs: key players in the breast cancer progression and immune cell’s modulation

Experimental Cell Research, Год журнала: 2025, Номер unknown, С. 114531 - 114531

Опубликована: Март 1, 2025

Язык: Английский

---

Emerging role and clinical applications of circular RNAs in human diseases

Functional & Integrative Genomics, Год журнала: 2025, Номер 25(1)

Опубликована: Март 28, 2025

Язык: Английский

---